Phytochemical Compounds and Protection from Cardiovascular Diseases: A State of the Art

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Pagliaro, Beniamino ^a   Santolamazza, Caterina ^a   Simonelli, Francesca ^a   Rubattu, Speranza ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; CURCUMIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE B; RESVERATROL; SIRTUIN 1; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NRF2; UNCOUPLING PROTEIN 2; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; PROTECTIVE AGENT; STILBENE DERIVATIVE;

ANTIAPOPTOTIC ACTIVITY; ANTIARRHYTHMIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BERRY; BRAIN ISCHEMIA; BRASSICA OLERACEA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; DRUG ACTIVITY; DRUG STRUCTURE; DYSLIPIDEMIA; GRAPE; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PEANUT; PHYTOCHEMISTRY; POLYGONUM CUSPIDATUM; RED WINE; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; MOUSE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MICE; PHYTOCHEMICALS; PLANT EXTRACTS; PROTECTIVE AGENTS; STILBENES;

EID: 84945346213     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/918069     Document Type: Review

References (206)

1. D. Mozaffarian, E. J. Benjamin, A. S. Go et al., "Executive summary: heart disease and stroke statistics-2015 update: a report from the American Heart Association," Circulation, vol. 131, no. 4, pp. 434-441, 2015.
2. Y. Qin, F. Shu, Y. Zeng et al., "Daidzein supplementation decreases serum triglyceride and uric acid concentrations in hypercholesterolemic adults with the effect on triglycerides being greater in those with the GA compared with the GG genotype of ESR-β RsaI," Journal of Nutrition, vol. 144, no. 1, pp. 49-54, 2014.
3. E. Chan, C. Y.-K. Wong, C.-W. Wan et al., "Evaluation of antioxidant capacity of root of Scutellaria baicalensis Georgi, in comparison with roots of Polygonum multiflorum Thunb and Panax ginseng CA Meyer," The American Journal of Chinese Medicine, vol. 38, no. 4, pp. 815-827, 2010.
4. J. Burns, T. Yokota, H. Ashihara, M. E. J. Lean, and A. Crozier, "Plant foods and herbal sources of resveratrol," Journal of Agricultural and Food Chemistry, vol. 50, no. 11, pp. 3337-3340, 2002.
5. D. Mikulski, R. Górniak, and M. Molski, "A theoretical study of the structure-radical scavenging activity of trans-resveratrol analogues and cis-resveratrol in gas phase and water environment," European Journal of Medicinal Chemistry, vol. 45, no. 3, pp. 1015-1027, 2010.
6. D. K. Das, S. Mukherjee, and D. Ray, "Resveratrol and redwine, healthy heart and longevity," Heart Failure Reviews, vol. 15, no. 5, pp. 467-477, 2010.
7. S. Renaud and M. de Lorgeril, "Wine, alcohol, platelets, and the French paradox for coronary heart disease, "TheLancet, vol. 339, no. 8808, pp. 1523-1526, 1992.
8. C.-H. Cottart, V. Nivet-Antoine, and J.-L. Beaudeux, "Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans," Molecular Nutrition and Food Research, vol. 58, no. 1, pp. 7-21, 2014.
9. H. Yun, S. Park, M.-J. Kim et al., "AMP-activated protein kinase mediates the antioxidant effects of resveratrol through regulation of the transcription factor FoxO1," FEBS Journal, vol. 281, no. 19, pp. 4421-4438, 2014.
10. S. M. Saud, W. Li, N. L. Morris et al., "Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression," Carcinogenesis, vol. 35, no. 12, pp. 2778-2786, 2014.
11. X. Cao, T. Luo, X. Luo, and Z. Tang, "Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice," Hypertension Research, vol. 37, no. 9, pp. 803-810, 2014.
12. M. J. Zarzuelo, R. López-Sepúlveda, M. Sánchez et al., "SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging," Biochemical Pharmacology, vol. 85, no. 9, pp. 1288-1296, 2013.
13. M. Pacholec, J. E. Bleasdale, B. Chrunyk et al., "SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1, "The Journal of Biological Chemistry, vol. 285, no. 11, pp. 8340-8351, 2010.
14. G. Spanier, H. Xu, N. Xia et al., "Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4)," Journal of Physiology and Pharmacology, vol. 60, supplement 4, pp. 111-116, 2009.
15. M. Tanno, A. Kuno, T. Yano et al., "Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure," The Journal of Biological Chemistry, vol. 285, no. 11, pp. 8375-8382, 2010.
16. J. J. Moreno, "Resveratrol modulates arachidonic acid release, prostaglandin synthesis, and 3T6 fibroblast growth," Journal of Pharmacology and ExperimentalTherapeutics, vol. 294, no. 1, pp. 333-338, 2000.
17. J. K. Kundu, Y. K. Shin, S. H. Kim, and Y.-J. Surh, "Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity," Carcinogenesis, vol. 27, no. 7, pp. 1465-1474, 2006.
18. L. Yang, J. Zhang, C. Yan et al., "SIRT1 regulates CD40 expression induced by TNF-α viaNF-κB pathway in endothelial cells," Cellular Physiology and Biochemistry, vol. 30, no. 5, pp. 1287-1298, 2012.
19. J. P. Cullen, D. Morrow, Y. Jin et al., "Resveratrol, a polyphenolic phytostilbene, inhibits endothelial monocyte chemotactic protein-1 synthesis and secretion," Journal of Vascular Research, vol. 44, no. 1, pp. 75-84, 2007.
20. C. C. Wu, C. I. Wu, W. Y. Wang, and Y. C. Wu, "Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins," PlantaMedica, vol. 73, no. 5, pp. 439-443, 2007.
21. K. H. Lin, G. Hsiao, C. M. Shih, D. S. Chou, and J. R. Sheu, "Mechanisms of resveratrol-induced platelet apoptosis," Cardiovascular Research, vol. 83, no. 3, pp. 575-585, 2009.
22. M.Y. Shen, G. Hsiao, C. L. Liu et al., "Inhibitorymechanisms of resveratrol in platelet activation: pivotal roles of p38MAPK and NO/cyclic GMP," British Journal of Haematology, vol. 139, no. 3, pp. 475-485, 2007.
23. B. Olas, B. Wachowicz, H. Holmsen, and M. H. Fukami, "Resveratrol inhibits polyphosphoinositide metabolism in activated platelets," Biochimica et Biophysica Acta - Biomembranes, vol. 1714, no. 2, pp. 125-133, 2005.
24. J. W. E. Rush, J. Quadrilatero, A. S. Levy, and R. J. Ford, "Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats," Experimental Biology and Medicine, vol. 232, no. 6, pp. 814-822, 2007.
25. A. Novakovic, L. Gojkovic-Bukarica, M. Peric et al., "The mechanism of endothelium-independent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery," Journal of Pharmacological Sciences, vol. 101, no. 1, pp. 85-90, 2006.
26. J. Zou, Z. Wang, Y. Huang, K. Cao, and J. Wu, "Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits," International Journal ofMolecular Medicine, vol. 11, no. 3, pp. 317-320, 2003.
27. J.-C. Liu, J.-J. Chen, P. Chan, C.-F. Cheng, and T.-H. Cheng, "Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol," Hypertension, vol. 42, no. 6, pp. 1198-1205, 2003.
28. H.-J. Ma, Y.-K. Cao, Y.-X. Liu, R. Wang, and Y.-M. Wu, "Microinjection of resveratrol into rostral ventrolateral medulla decreases sympathetic vasomotor tone through nitric oxide and intracellular Ca2+ in anesthetized male rats," Acta Pharmacologica Sinica, vol. 29, no. 8, pp. 906-912, 2008.
29. S. R. Bhatt, M. F. Lokhandwala, and A. A. Banday, "Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats," European Journal of Pharmacology, vol. 667, no. 1-3, pp. 258-264, 2011.
30. H. Z. Toklu, O. Şehirli, M. Erşahin et al., "Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats," Journal of Pharmacy and Pharmacology, vol. 62, no. 12, pp. 1784-1793, 2010.
31. Z. Liu, Y. Song, X. Zhang et al., "Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized ratmodel," Clinical and Experimental Pharmacology and Physiology, vol. 32, no. 12, pp. 1049-1054, 2005.
32. V. Chan, A. Fenning, A. Iyer, A. Hoey, and L. Brown, "Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats," Current Pharmaceutical Biotechnology, vol. 12, no. 3, pp. 429-436, 2011.
33. M.-C. Aubin, C. Lajoie, R. Clément, H. Gosselin, A. Calderone, and L. P. Perrault, "Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol," Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 3, pp. 961-968, 2008.
34. U. Förstermann and H. Li, "Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling," British Journal of Pharmacology, vol. 164, no. 2, pp. 213-223, 2011.
35. I. Mattagajasingh, C.-S. Kim, A. Naqvi et al., "SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 37, pp. 14855-14860, 2007.
36. H. Li and U. Förstermann, "Nitric oxide in the pathogenesis of vascular disease," Journal of Pathology, vol. 190, no. 3, pp. 244-254, 2000.
37. Y. Liu, W. Ma, P. Zhang, S. He, and D. Huang, "Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials," Clinical Nutrition, vol. 34, no. 1, pp. 27-34, 2015.
38. A. Carrizzo, A. Puca, A. Damato et al., "Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism," Hypertension, vol. 62, no. 2, pp. 359-366, 2013.
39. R.H.X. Wong, N.M. Berry, A.M. Coates et al., "Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults," Journal of Hypertension, vol. 31, no. 9, pp. 1819-1827, 2013.
40. K. Magyar, R. Halmosi, A. Palfi et al., "Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease," Clinical Hemorheology and Microcirculation, vol. 50, no. 3, pp. 179-187, 2012.
41. T. Yashiro, M. Nanmoku, M. Shimizu, J. Inoue, and R. Sato, "Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element-binding proteins," Atherosclerosis, vol. 220, no. 2, pp. 369-374, 2012.
42. J. Xiao, J. Song, V. Hodara et al., "Protective effects of resveratrol on TNF-α-induced endothelial cytotoxicity in baboon femoral arterial endothelial cells," Journal of Diabetes Research, vol. 2013, Article ID 185172, 9 pages, 2013.
43. D.-W. Park, K. Baek, J.-R. Kim et al., "Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species andmonocyte chemotactic protein-1," Experimental and Molecular Medicine, vol. 41, no. 3, pp. 171-179, 2009.
44. J. P. Cullen, D. Morrow, Y. Jin et al., "Resveratrol inhibits expression and binding activity of themonocyte chemotactic protein-1 receptor, CCR2, on THP-1 monocytes," Atherosclerosis, vol. 195, no. 1, pp. e125-e133, 2007.
45. I. Voloshyna, O. Hai, M. J. Littlefield, S. Carsons, and A. B. Reiss, "Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARgamma and adenosine," European Journal of Pharmacology, vol. 698, no. 1-3, pp. 299-309, 2013.
46. A. Csiszar, D. Sosnowska, M. Wang, E. G. Lakatta, W. E. Sonntag, and Z. Ungvari, "Age-associated proinflammatory secretory phenotype in vascular smooth muscle cells from the non-human primate macaca mulatta: reversal by resveratrol treatment," Journals of Gerontology - Series A: Biological Sciences and Medical Sciences, vol. 67, no. 8, pp. 811-820, 2012.
47. L. Li, P. Gao, H. Zhang et al., "SIRT1 inhibits angiotensin II-induced vascular smooth muscle cell hypertrophy," Acta Biochimica et Biophysica Sinica, vol. 43, no. 2, pp. 103-109, 2011.
48. A. Y. Göçmen, D. Burgucu, and S. Gümüşlü, "Effect of resveratrol on platelet activation in hypercholesterolemic rats: CD40-CD40l system as a potential target," Applied Physiology, Nutrition and Metabolism, vol. 36, no. 3, pp. 323-330, 2011.
49. Z. Wang, J. Zou, K. Cao, T.-C. Hsieh, Y. Huang, and J. M. Wu, "Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels," International Journal of Molecular Medicine, vol. 16, no. 4, pp. 533-540, 2005.
50. G.-M. Do, E.-Y. Kwon, H.-J. Kim et al., "Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice," Biochemical and Biophysical Research Communications, vol. 374, no. 1, pp. 55-59, 2008.
51. Q. Chen, E. Wang, L. Ma, and P. Zhai, "Dietary resveratrol increases the expression of hepatic 7-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice," Lipids in Health and Disease, vol. 11, article 56, 2012.
52. A. Sahebkar, "Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials," Nutrition Reviews, vol. 71, no. 12, pp. 822-835, 2013.
53. J. K. Bhatt, S. Thomas, and M. J. Nanjan, "Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus," Nutrition Research, vol. 32, no. 7, pp. 537-541, 2012.
54. C. Militaru, I. Donoiu, A. Craciun, I. D. Scorei, A.M. Bulearca, and R. I. Scorei, "Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life," Nutrition, vol. 29, no. 1, pp. 178-183, 2013.
55. S. Chen, Z. Li, W. Li, Z. Shan, and W. Zhu, "Resveratrol inhibits cell differentiation in 3T3-L1 adipocytes via activation ofAMPK, "Canadian Journal of Physiology&Pharmacology, vol. 89, no. 11, pp. 793-799, 2011.
56. I. Mader, M. Wabitsch, K.-M. Debatin, P. Fischer-Posovszky, and S. Fulda, "Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis," The FASEB Journal, vol. 24, no. 6, pp. 1997-2009, 2010.
57. A. Lasa, M. Schweiger, P. Kotzbeck et al., "Resveratrol regulates lipolysis via adipose triglyceride lipase," Journal of Nutritional Biochemistry, vol. 23, no. 4, pp. 379-384, 2012.
58. G. Alberdi, V. M. Rodríguez, J. Miranda et al., "Changes in white adipose tissuemetabolism induced by resveratrol in rats," Nutrition & Metabolism, vol. 8, no. 1, p. 29, 2011.
59. S. Koren and I. G. Fantus, "Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus," Best Practice and Research in Clinical Endocrinology and Metabolism, vol. 21, no. 4, pp. 621-640, 2007.
60. S. M. Grundy, I. J. Benjamin, G. L. Burke et al., "Diabetes and cardiovascular disease: a statement for healthcare professionals fromthe AmericanHeart Association," Circulation, vol. 100, no. 10, pp. 1134-1146, 1999.
61. S. Frojdo, C. Durand, L. Molin et al., "Phosphoinositide 3- kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1," Molecular and Cellular Endocrinology, vol. 335, no. 2, pp. 166-176, 2011.
62. Y.-H. Jing, K.-H. Chen, S.-H. Yang, P.-C. Kuo, and J.-K. Chen, "Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling," Diabetes/Metabolism Research and Reviews, vol. 26, no. 3, pp. 212-222, 2010.
63. M. Thirunavukkarasu, S. V. Penumathsa, S. Koneru et al., "Resveratrol alleviates cardiac dysfunction in streptozotocininduced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase," Free Radical Biology and Medicine, vol. 43, no. 5, pp. 720-729, 2007.
64. M. Sulaiman, M. J. Matta, N. R. Sunderesan, M. P. Gupta, M. Periasamy, and M. Gupta, "Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calciumATPase and improves cardiac function in diabetic cardiomyopathy," The American Journal of Physiology - Heart and Circulatory Physiology, vol. 298, no. 3, pp. H833-H843, 2010.
65. H. Zhang, B. Morgan, B. J. Potter et al., "Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging," The American Journal of Physiology - Heart and Circulatory Physiology, vol. 299, no. 4, pp. H985- H994, 2010.
66. J. P. Crandall, V. Oram, G. Trandafirescu et al., "Pilot study of resveratrol in older adults with impaired glucose tolerance," Journals of Gerontology - Series A: Biological Sciences and Medical Sciences, vol. 67, no. 12, pp. 1307-1312, 2012.
67. M. Méndez-del Villar, M. González-Ortiz, E. Martínez- Abundis, K. G. Pérez-Rubio, and R. Lizárraga-Valdez, "Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion," Metabolic Syndrome and Related Disorders, vol. 12, no. 10, pp. 497-501, 2014.
68. V. S. Chachay, G. A. Macdonald, J. H. Martin et al., "Resveratrol does not benefit patients with nonalcoholic fatty liver disease," Clinical Gastroenterology and Hepatology, vol. 12, no. 12, pp. 2092-2103.e6, 2014.
69. S. Dash, C. Xiao, C. Morgantini, L. Szeto, and G. F. Lewis, "High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 12, pp. 2895-2901, 2013.
70. J. Tomé-Carneiro, M. Gonzálvez, M. Larrosa et al., "Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease," Cardiovascular Drugs and Therapy, vol. 27, no. 1, pp. 37-48, 2013.
71. D. De Groote, K. van Belleghem, J. Devire, W. Van Brussel, A. Mukaneza, and L. Amininejad, "Effect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects," Annals of Nutrition and Metabolism, vol. 61, no. 1, pp. 15-24, 2012.
72. L.-M. Hung, M.-J. Su, and J.-K. Chen, "Resveratrol protects myocardial ischemia-reperfusion injury through both NOdependent and NO-independent mechanisms," Free Radical Biology and Medicine, vol. 36, no. 6, pp. 774-781, 2004.
73. X.-B. Wang, J. Huang, J.-G. Zou et al., "Effects of resveratrol on number and activity of endothelial progenitor cells from human peripheral blood," Clinical and Experimental Pharmacology and Physiology, vol. 34, no. 11, pp. 1109-1115, 2007.
74. C.-J. Chen, W. Yu, Y.-C. Fu, X. Wang, J.-L. Li, and W. Wang, "Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway," Biochemical and Biophysical Research Communications, vol. 378, no. 3, pp. 389-393, 2009.
75. N. Gurusamy, I. Lekli, S. Mukherjee et al., "Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway," Cardiovascular Research, vol. 86, no. 1, pp. 103-112, 2010.
76. S. Kaga, L. Zhan, M. Matsumoto, and N. Maulik, "Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor," Journal of Molecular and Cellular Cardiology, vol. 39, no. 5, pp. 813-822, 2005.
77. N. Gurusamy, D. Ray, I. Lekli, and D. K. Das, "Red wine antioxidant resveratrol-modified cardiac stem cells regenerate infarcted myocardium," Journal of Cellular and Molecular Medicine, vol. 14, no. 9, pp. 2235-2239, 2010.
78. P. Mukhopadhyay, S. Mukherjee, K. Ahsan, A. Bagchi, P. Pacher, and D. K. Das, "Restoration of alteredMicroRNA expression in the ischemic heart with resveratrol," PLoS ONE, vol. 5, no. 12, Article ID e15705, 2010.
79. M. Shalwala, S.-G. Zhu, A. Das, F. N. Salloum, L. Xi, and R. C. Kukreja, "Sirtuin 1 (SIRT1) activation mediates sildenafil induced delayed cardioprotection against ischemia-reperfusion injury in mice," PLoS ONE, vol. 9, no. 1, Article ID e86977, 2014.
80. H. Kanamori, G. Takemura, K. Goto et al., "Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway," American Journal of Pathology, vol. 182, no. 3, pp. 701-713, 2013.
81. A. Barseghian, D. Gawande, and M. Bajaj, "Adiponectin and vulnerable atherosclerotic plaques," Journal of the American College of Cardiology, vol. 57, no. 7, pp. 761-770, 2011.
82. H. Maruyoshi, S. Kojima, T. Funahashi et al., "Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina," Thrombosis and Haemostasis, vol. 91, no. 5, pp. 1026-1030, 2004.
83. B. N. Zordoky, I. M. Robertson, and J. R. Dyck, "Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases," Biochimica et Biophysica Acta, vol. 1852, no. 6, pp. 1155-1177, 2014.
84. S. J. Thandapilly, P. Wojciechowski, J. Behbahani et al., "Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure," American Journal of Hypertension, vol. 23, no. 2, pp. 192-196, 2010.
85. S. Rimbaud, M. Ruiz, J. Piquereau et al., "Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure," PLoS ONE, vol. 6, no. 10, Article ID e26391, 2011.
86. P. Wojciechowski, D. Juric, X. L. Louis et al., "Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats," Journal of Nutrition, vol. 140, no. 5, pp. 962-968, 2010.
87. P. Ferroni, D. Della-Morte, R. Palmirotta et al., "Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention," Rejuvenation Research, vol. 14, no. 3, pp. 293-308, 2011.
88. X. S. Gu, Z. B. Wang, Z. Ye et al., "Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure," Genetics and Molecular Research, vol. 13, no. 1, pp. 323-335, 2014.
89. Y. Yoshida, T. Shioi, and T. Izumi, "Resveratrol ameliorates experimental autoimmune myocarditis," Circulation Journal, vol. 71, no. 3, pp. 397-404, 2007.
90. W. Xuan, B. Wu, C. Chen et al., "Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine," Critical Care Medicine, vol. 40, no. 11, pp. 3026-3033, 2012.
91. M. M. Sung, S. K. Das, J. Levasseur et al., "Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism," Circulation: Heart Failure, vol. 8, no. 1, pp. 128-137, 2015.
92. D. Clark, U. I. Tuor, R. Thompson et al., "Protection against recurrent stroke with resveratrol: endothelial protection," PLoS ONE, vol. 7, no. 10, Article IDe47792, 2012.
93. F. Simão, A. S. Pagnussat, J. H. Seo et al., "Pro-angiogenic effects of resveratrol in brain endothelial cells: nitric oxide-mediated regulation of vascular endothelial growth factor and metalloproteinases," Journal of Cerebral Blood Flow and Metabolism, vol. 32, no. 5, pp. 884-895, 2012.
94. D. M. Arrick, H. Sun, K. P. Patel, and W. G. Mayhan, "Chronic resveratrol treatment restores vascular responsiveness of cerebral arterioles in type 1 diabetic rats," The American Journal of Physiology - Heart and Circulatory Physiology, vol. 301, no. 3, pp. H696-H703, 2011.
95. S. S. Huang, M. C. Tsai, C. L. Chih, L. M. Hung, and S. K. Tsai, "Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia," Life Sciences, vol. 69, no. 9, pp. 1057-1065, 2001.
96. H.-C. Chang, Y.-T. Tai, Y.-G. Cherng et al., "Resveratrol attenuates high-fat diet-induced disruption of the blood-brain barrier and protects brain neurons from apoptotic insults," Journal of Agricultural and Food Chemistry, vol. 62, no. 15, pp. 3466-3475, 2014.
97. J. Ren, C. Fan, N. Chen, J. Huang, and Q. Yang, "Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in Rats," Neurochemical Research, vol. 36, no. 12, pp. 2352-2362, 2011.
98. D. Della-Morte, K. R. Dave, R.A. DeFazio, Y. C. Bao, A. P. Raval, and M. A. Perez-Pinzon, "Resveratrol pretreatment protects rat brain fromcerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway," Neuroscience, vol. 159, no. 3, pp. 993-1002, 2009.
99. E. L. Wightman, J. L. Reay, C. F. Haskell, G. Williamson, T. P. Dew, and D. O. Kennedy, "Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation," British Journal of Nutrition, vol. 112, no. 2, pp. 203-213, 2014.
100. M. H. Arafa, N. S. Mohammad, H. H. Atteia, and H. R. Abd- Elaziz, "Protective effect of resveratrol against doxorubicininduced cardiac toxicity and fibrosis in male experimental rats," Journal of Physiology and Biochemistry, vol. 70, no. 3, pp. 701-711, 2014.
101. G.-Y. Wang, Y.-M. Wang, L.-N. Zhang et al., "Effect of resveratrol on heart function of rats with adriamycin-induced heart failure," Zhongguo Zhong Yao Za Zhi, vol. 32, no. 15, pp. 1563-1565, 2007.
102. S. Wang, P. Song, and M.-H. Zou, "Inhibition of AMP-activated protein kinase α (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1, "TheJournal of Biological Chemistry, vol. 287, no. 11, pp. 8001-8012, 2012.
103. Y. Zhang, Y. Liu, T. Wang et al., "Resveratrol, a natural ingredient of grape skin: antiarrhythmic efficacy and ionic mechanisms," Biochemical and Biophysical Research Communications, vol. 340, no. 4, pp. 1192-1199, 2006.
104. Y. R. Chen, F. F. Yi, X. Y. Li et al., "Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction," Cardiovascular Drugs and Therapy, vol. 22, no. 6, pp. 479-485, 2008.
105. I. Baczko, D. Liknes, W. Yang et al., "Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation," British Journal of Pharmacology, vol. 171, no. 1, pp. 92-106, 2014.
106. M. Akhlaghi and B. Bandy, "Dietary broccoli sprouts protect against myocardial oxidative damage and cell death during ischemia-reperfusion," Plant Foods for Human Nutrition, vol. 65, no. 3, pp. 193-199, 2010.
107. H. A. H. Kataya and A. A. Hamza, "Red cabbage (Brassica oleracea) ameliorates diabetic nephropathy in rats," Evidence- Based Complementary and Alternative Medicine, vol. 5, no. 3, pp. 281-287, 2008.
108. S. Y. Kim, S. Yoon, S. M. Kwon, K. S. Park, and Y. C. Lee- Kim, "Kale Juice improves coronary artery disease risk factors in hypercholesterolemic men," Biomedical and Environmental Sciences, vol. 21, no. 2, pp. 91-97, 2008.
109. R. Domínguez-Perles, P. Mena, C. García-Viguera, and D. A. Moreno, "Brassica foods as a dietary source of vitamin C: a review," Critical Reviews in Food Science and Nutrition, vol. 54, no. 8, pp. 1076-1091, 2014.
110. R. Mithen, R. Bennett, and J. Marquez, "Glucosinolate biochemical diversity and innovation in the Brassicales," Phytochemistry, vol. 71, no. 17-18, pp. 2074-2086, 2010.
111. C. A. Houghton, R. G. Fassett, and J. S. Coombes, "Sulforaphane: translational research from laboratory bench to clinic," Nutrition Reviews, vol. 71, no. 11, pp. 709-726, 2013.
112. C. C. Conaway, S. M. Getahun, L. L. Liebes et al., "Disposition of glucosinolates and sulforaphane in humans after ingestion of steamed and fresh broccoli," Nutrition and Cancer, vol. 38, no. 2, pp. 168-178, 2000.
113. M. Vermeulen, H. J.M. van Rooijen, and W.H. J. Vaes, "Analysis of isothiocyanate mercapturic acids in urine: a biomarker for cruciferous vegetable intake," Journal of Agricultural and Food Chemistry, vol. 51, no. 12, pp. 3554-3559, 2003.
114. S. A. Ritz, J. Wan, and D. Diaz-Sanchez, "Sulforaphanestimulated phase II enzyme induction inhibits cytokine production by airway epithelial cells stimulatedwith diesel extract, "The American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 292, no. 1, pp. L33-L39, 2007.
115. M.-H. Oak, J. E. Bedoui, S. V. F. Madeira, K. Chalupsky, and V. B. Schini-Kerth, "Delphinidin and cyanidin inhibit PDGFABinduced VEGF release in vascular smooth muscle cells by preventing activation of p38 MAPK and JNK," British Journal of Pharmacology, vol. 149, no. 3, pp. 283-290, 2006.
116. A. Palfi, E. Bartha, L. Copf et al., "Alcohol-free red wine inhibits isoproterenol-induced cardiac remodeling in rats by the regulation of Akt1 and protein kinase C α/β II," Journal of Nutritional Biochemistry, vol. 20, no. 6, pp. 418-425, 2009.
117. S. Rubattu, S. di Castro, M. Cotugno et al., "Protective effects of Brassica oleracea sprouts extract toward renal damage in highsalt- fed SHRSP: role of AMPK/PPARα/UCP2 axis," Journal of Hypertension, vol. 33, no. 7, pp. 1465-1479, 2015.
118. M. Zakkar, K. van der Heiden, L. A. Luong et al., "Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 11, pp. 1851-1857, 2009.
119. M. Murashima, S. Watanabe, X.-G. Zhuo, M. Uehara, and A. Kurashige, "Phase 1 study of multiple biomarkers for metabolism and oxidative stress after one-week intake of broccoli sprouts," BioFactors, vol. 22, no. 1-4, pp. 271-275, 2004.
120. L. Wu, M. H. N. Ashraf, M. Facci et al., "Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system," Proceedings of theNational Academy of Sciences of the United States of America, vol. 101, no. 18, pp. 7094-7099, 2004.
121. M. H. Noyan-Ashraf, L. Wu, R. Wang, and B. H. J. Juurlink, "Dietary approaches to positively influence fetal determinants of adult health," The FASEB Journal, vol. 20, no. 2, pp. 371-373, 2006.
122. A. R. Rechner and C. Kroner, "Anthocyanins and colonic metabolites of dietary polyphenols inhibit platelet function," Thrombosis Research, vol. 116, no. 4, pp. 327-334, 2005.
123. M. Garcia-Alonso, A.-M. Minihane, G. Rimbach, J. C. Rivas- Gonzalo, and S. de Pascual-Teresa, "Red wine anthocyanins are rapidly absorbed in humans and affect monocyte chemoattractant protein 1 levels and antioxidant capacity of plasma," Journal of Nutritional Biochemistry, vol. 20, no. 7, pp. 521-529, 2009.
124. D. R. Bell and K. Gochenaur, "Direct vasoactive andvasoprotective properties of anthocyanin-rich extracts," Journal of Applied Physiology, vol. 100, no. 4, pp. 1164-1170, 2006.
125. M.-C. Toufektsian, M. de Lorgeril, N. Nagy et al., "Chronic dietary intake of plant-derived anthocyanins protects the rat heart against ischemia-reperfusion injury," Journal of Nutrition, vol. 138, no. 4, pp. 747-752, 2008.
126. M. Xia, W. Ling, H. Zhu et al., "Anthocyanin prevents CD40- activated proinflammatory signaling in endothelial cells by regulating cholesterol distribution," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 3, pp. 519-524, 2007.
127. M. Hämäläinen, R. Nieminen, P. Vuorela, M. Heinonen, and E. Moilanen, "Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF- κB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-κB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages," Mediators of Inflammation, vol. 2007, Article ID 45673, 10 pages, 2007.
128. T. M. Scarabelli, S. Mariotto, S. Abdel-Azeim et al., "Targeting STAT1 by myricetin and delphinidin provides efficient protection of the heart from ischemia/reperfusion-induced injury," FEBS Letters, vol. 583, no. 3, pp. 531-541, 2009.
129. Y. Jia, J.-Y. Kim, H.-J. Jun et al., "Cyanidin is an agonistic ligand for peroxisome proliferator-activated receptor-alpha reducing hepatic lipid," Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, vol. 1831, no. 4, pp. 698-708, 2013.
130. J. D. Clarke, K. Riedl, D. Bella, S. J. Schwartz, J. F. Stevens, and E. Ho, "Comparison of isothiocyanate metabolite levels and histone deacetylase activity in human subjects consuming broccoli sprouts or broccoli supplement," Journal of Agricultural and Food Chemistry, vol. 59, no. 20, pp. 10955-10963, 2011.
131. J. M. Cramer and E. H. Jeffery, "Sulforaphane absorption and excretion following ingestion of a semi-purified broccoli powder rich in glucoraphanin and broccoli sprouts in healthy men," Nutrition and Cancer, vol. 63, no. 2, pp. 196-201, 2011.
132. Z. Bahadoran, P. Mirmiran, F. Hosseinpanah, A. Rajab, G. Asghari, and F. Azizi, "Broccoli sprouts powder could improve serum triglyceride and oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients: a randomized double-blind placebocontrolled clinical trial," Diabetes Research and Clinical Practice, vol. 96, no. 3, pp. 348-354, 2012.
133. A. Jennings, A. A. Welch, S. J. Fairweather-Tait et al., "Higher anthocyanin intake is associated with lower arterial stiffness and central blood pressure in women," The American Journal of Clinical Nutrition, vol. 96, no. 4, pp. 781-788, 2012.
134. P. J. Curtis, P. A. Kroon, W. J. Hollands et al., "Cardiovascular disease risk biomarkers and liver and kidney function are not altered in postmenopausal women after ingesting an elderberry extract rich in anthocyanins for 12 weeks," Journal of Nutrition, vol. 139, no. 12, pp. 2266-2271, 2009.
135. B. B. Aggarwal and K. B. Harikumar, "Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases," International Journal of Biochemistry and Cell Biology, vol. 41, no. 1, pp. 40-59, 2009.
136. W. Wongcharoen and A. Phrommintikul, "The protective role of curcumin in cardiovascular diseases," International Journal of Cardiology, vol. 133, no. 2, pp. 145-151, 2009.
137. W. Duan, Y. Yang, J. Yan et al., "The effects of curcumin post-treatment against myocardial ischemia and reperfusion by activation of the JAK2/STAT3 signaling pathway," Basic Research in Cardiology, vol. 107, no. 3, article 263, 2012.
138. Y. Pu, H. Zhang, P. Wang et al., "Dietary curcumin ameliorates aging-related cerebrovascular dysfunction through the ampk/uncoupling protein 2 pathway," Cellular Physiology and Biochemistry, vol. 32, no. 5, pp. 1167-1177, 2013.
139. J. Wu, Q. Li, X. Wang et al., "Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway," PLoS ONE, vol. 8, no. 3, Article ID e59843, 2013.
140. Z.-H. Deng, J. Liao, J.-Y. Zhang et al., "Localized leptin release may be an important mechanism of curcumin action after acute ischemic injuries," Journal of Trauma and Acute Care Surgery, vol. 74, no. 4, pp. 1044-1051, 2013.
141. Y. S. Kim, Y. Ahn, M. H. Hong et al., "Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells," Journal of Cardiovascular Pharmacology, vol. 50, no. 1, pp. 41-49, 2007.
142. A. Sahebkar, "Are curcuminoids effective C-reactive proteinlowering agents in clinical practice? Evidence from a metaanalysis," Phytotherapy Research, vol. 28, no. 5, pp. 633-642, 2014.
143. F. E. Parodi, D. Mao, T. L. Ennis, M. B. Pagano, and R. W. Thompson, "Oral administration of diferuloylmethane (curcumin) suppresses proinflammatory cytokines and destructive connective tissue remodeling in experimental abdominal aortic aneurysms," Annals of Vascular Surgery, vol. 20, no. 3, pp. 360-368, 2006.
144. Y. Pan, G. Zhu, Y. Wang et al., "Attenuation of high-glucoseinduced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart," Journal ofNutritional Biochemistry, vol. 24, no. 1, pp. 146-155, 2013.
145. P. Manikandan, M. Sumitra, S. Aishwarya, B. M. Manohar, B. Lokanadam, and R. Puvanakrishnan, "Curcumin modulates free radical quenching in myocardial ischaemia in rats," The International Journal of Biochemistry & Cell Biology, vol. 36, no. 10, pp. 1967-1980, 2004.
146. H. Farhangkhoee, Z. A. Khan, S. Chen, and S. Chakrabarti, "Differential effects of curcumin on vasoactive factors in the diabetic rat heart," Nutrition and Metabolism, vol. 3, article 27, 2006.
147. R. Motterlini, R. Foresti, R. Bassi, and C. J. Green, "Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress," Free Radical Biology and Medicine, vol. 28, no. 8, pp. 1303-1312, 2000.
148. J. Trujillo, L. F. Granados-Castro, C. Zazueta, A. C. Andérica- Romero, Y. I. Chirino, and J. Pedraza-Chaverrí, "Mitochondria as a target in the therapeutic properties of curcumin," Archiv der Pharmazie, vol. 347, no. 12, pp. 873-884, 2014.
149. X. Yang, D. P. Thomas, X. Zhang et al., "Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 1, pp. 85-90, 2006.
150. H.-W. Chen and H.-C. Huang, "Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells," British Journal of Pharmacology, vol. 124, no. 6, pp. 1029-1040, 1998.
151. Y. Hua, J. Dolence, S. Ramanan, J. Ren, and S. Nair, "Bisdemethoxycurcumin inhibits PDGF-induced vascular smooth muscle cell motility and proliferation, "Molecular Nutrition and Food Research, vol. 57, no. 9, pp. 1611-1618, 2013.
152. C. Sumbilla, D. Lewis, T. Hammerschmidt, and G. Inesi, "The slippage of the Ca2+ pump and its control by anions and curcumin in skeletal and cardiac sarcoplasmic reticulum," The Journal of Biological Chemistry, vol. 277, no. 16, pp. 13900-13906, 2002.
153. J.-M. Zingg, S. T. Hasan, and M. Meydani, "Molecular mechanisms of hypolipidemic effects of curcumin," BioFactors, vol. 39, no. 1, pp. 101-121, 2013.
154. J. L. Quiles, M. D. Mesa, C. L. Ramírez-Tortosa et al., "Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 7, pp. 1225-1231, 2002.
155. C. Nirmala and R. Puvanakrishnan, "Protective role of curcumin against isoproterenol induced myocardial infarction in rats, "Molecular and Cellular Biochemistry, vol. 159, no. 2, pp. 85-93, 1996.
156. N.-P. Wang, Z.-F. Wang, S. Tootle, T. Philip, and Z.-Q. Zhao, "Curcumin promotes cardiac repair and ameliorates cardiac dysfunction following myocardial infarction," British Journal of Pharmacology, vol. 167, no. 7, pp. 1550-1562, 2012.
157. C.-H. Yeh, T.-P. Chen, Y.-C. Wu, Y.-M. Lin, and P. Jing Lin, "Inhibition of NFκB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion," Journal of Surgical Research, vol. 125, no. 1, pp. 109-116, 2005.
158. T. Morimoto, Y. Sunagawa, T. Kawamura et al., "The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats," Journal of Clinical Investigation, vol. 118, no. 3, pp. 868-878, 2008.
159. N. Venkatesan, "Curcumin attenuation of acute adriamycin myocardial toxicity in rats," British Journal of Pharmacology, vol. 124, no. 3, pp. 425-427, 1998.
160. T.-H. Chen, Y.-C. Yang, J.-C. Wang, and J.-J. Wang, "Curcumin treatment protects against renal ischemia and reperfusion injury-induced cardiac dysfunction and myocardial injury," Transplantation Proceedings, vol. 45, no. 10, pp. 3546-3549, 2013.
161. V. Kakkar, S. K. Muppu, K. Chopra, and I. P. Kaur, "Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats," European Journal of Pharmaceutics and Biopharmaceutics, vol. 85, no. 3, part A, pp. 339-345, 2013.
162. N. Ahmad, S. Umar, M. Ashafaq et al., "A comparative study of PNIPAM nanoparticles of curcumin, demethoxycurcumin, and bisdemethoxycurcumin and their effects on oxidative stress markers in experimental stroke," Protoplasma, vol. 250, no. 6, pp. 1327-1338, 2013.
163. J. L. Funk, J. B. Frye, G. Davis-Gorman et al., "Curcuminoids limit neutrophil-mediated reperfusion injury in experimental stroke by targeting the endothelium," Microcirculation, vol. 20, no. 6, pp. 544-554, 2013.
164. K. B. Soni and R. Kuttan, "Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers," Indian Journal of Physiology and Pharmacology, vol. 36, no. 4, pp. 273-275, 1992.
165. I. Alwi, T. Santoso, S. Suyono et al., "The effect of curcumin on lipid level in patients with acute coronary syndrome," Acta Medica Indonesiana, vol. 40, no. 4, pp. 201-210, 2008.
166. S. Chuengsamarn, S. Rattanamongkolgul, B. Phonrat, R. Tungtrongchitr, and S. Jirawatnotai, "Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial," Journal of Nutritional Biochemistry, vol. 25, no. 2, pp. 144-150, 2014.
167. A. Sahebkar, "A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels," Clinical Nutrition, vol. 33, no. 3, pp. 406-414, 2014.
168. N. Akazawa, Y. Choi, A. Miyaki et al., "Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women," Nutrition Research, vol. 32, no. 10, pp. 795-799, 2012.
169. C. J. Pan, J. J. Tang, Z. Y. Shao, J. Wang, and N. Huang, "Improved blood compatibility of rapamycin-eluting stent by incorporating curcumin," Colloids and Surfaces B: Biointerfaces, vol. 59, no. 1, pp. 105-111, 2007.
170. Y.-X. Liu, C.-L. Xiao, Y.-X. Wang et al., "Synthesis, structureactivity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives," European Journal of Medicinal Chemistry, vol. 52, pp. 151-158, 2012.
171. H. Nishino, K. Kitagawa, H. Fujiki, and A. Iwashima, "Berberine sulfate inhibits tumor-promoting activity of teleocidin in twostage carcinogenesis onmouse skin," Oncology, vol. 43, no. 2, pp. 131-134, 1986.
172. J. Yao, W. Kong, and J. Jiang, "Learning fromberberine: treating chronic diseases through multiple targets," Science China Life Sciences, 2013.
173. C. W. Lau, X. Q. Yao, Z. Y. Chen, W. H. Ko, and Y. Huang, "Cardiovascular actions of berberine," Cardiovascular Drug Reviews, vol. 19, no. 3, pp. 234-244, 2001.
174. Q. Wang, M. Zhang, B. Liang, N. Shirwany, Y. Zhu, and M.-H. Zou, "Activation ofAMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2," PLoS ONE, vol. 6, no. 9, Article ID e25436, 2011.
175. L. K. Sarna, N. Wu, S.-Y. Hwang, Y. L. Siow, and O. Karmin, "Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages," Canadian Journal of Physiology and Pharmacology, vol. 88, no. 3, pp. 369-378, 2010.
176. C. Mo, L. Wang, J. Zhang et al., "The crosstalk betweenNrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice," Antioxidants and Redox Signaling, vol. 20, no. 4, pp. 574-588, 2014.
177. H. W. Jeong, K. C. Hsu, J.-W. Lee et al., "Berberine suppresses proinflammatory responses through AMPK activation in macrophages," American Journal of Physiology - Endocrinology and Metabolism, vol. 296, no. 4, pp. E955-E964, 2009.
178. X. Xie, X. Chang, L. Chen et al., "Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting the activation of RhoA/ROCK signaling," Molecular and Cellular Endocrinology, vol. 381, no. 1-2, pp. 56-65, 2013.
179. A.-W. Feng, W. Gao, G.-R. Zhou et al., "Berberine ameliorates COX-2 expression in rat small intestinal mucosa partially through PPARgamma pathway during acute endotoxemia," International Immunopharmacology, vol. 12, no. 1, pp. 182-188, 2012.
180. M. Xiao, L.N. Men, M.G. Xu, G. B. Wang, H. T. Lv, and C. Liu, "Berberine protects endothelial progenitor cell from damage of TNF-α via the PI3K/AKT/eNOS signaling pathway," European Journal of Pharmacology, vol. 743, pp. 11-16, 2014.
181. Y. Wang, Y. Huang, K. S. L. Lam et al., "Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase," Cardiovascular Research, vol. 82, no. 3, pp. 484-492, 2009.
182. S. Lee, H.-J. Lim, H.-Y. Park, K.-S. Lee, J.-H. Park, and Y. Jang, "Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model," Atherosclerosis, vol. 186, no. 1, pp. 29-37, 2006.
183. F. Zimetti, M. P. Adorni, N. Ronda, R. Gatti, F. Bernini, and E. Favari, "The natural compound berberine positively affects macrophage functions involved in atherogenesis," Nutrition, Metabolism and Cardiovascular Diseases, vol. 25, no. 2, pp. 195-201, 2015.
184. G. Derosa, P. Maffioli, and A. F. G. Cicero, "Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials," Expert Opinion on BiologicalTherapy, vol. 12, no. 8, pp. 1113-1124, 2012.
185. W. J. Kong, J. Wei, P. Abidi et al., "Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins," Nature Medicine, vol. 10, no. 12, pp. 1344-1351, 2004.
186. H. Li, B. Dong, S.W. Park, H.-S. Lee, W. Chen, and J. Liu, "Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine, "The Journal of Biological Chemistry, vol. 284, no. 42, pp. 28885-28895, 2009.
187. Y.-J. Jia, R.-X. Xu, J. Sun, Y. Tang, and J.-J. Li, "Enhanced circulating PCSK9 concentration by berberine through SREBP- 2 pathway in high fat diet-fed rats," Journal of Translational Medicine, vol. 12, article 103, 2014.
188. C.-W. Lau, X.-Q. Yao, Z.-Y. Chen, W.-H. Ko, and Y. Huang, "Cardiovascular actions of berberine," Cardiovascular Drug Reviews, vol. 19, no. 3, pp. 234-244, 2001.
189. L.-H. Wang, X.-L. Li, Q. Li et al., "Berberine alleviates ischemic arrhythmias via recovering depressed I(to) and I(Ca) currents in diabetic rats," Phytomedicine, vol. 19, no. 3-4, pp. 206-210, 2012.
190. A. Rodriguez-Menchaca, T. Ferrer-Villada, J. Lara, D. Fernandez, R. A. Navarro-Polanco, and J. A. Sanchez-Chapula, "Block of hERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels," Journal of Cardiovascular Pharmacology, vol. 47, no. 1, pp. 21-29, 2006.
191. F. R. Neto, "Electropharmacological effects of berberine on canine cardiac Purkinje fibres and ventricularmuscle and atrial muscle of the rabbit," British Journal of Pharmacology, vol. 108, no. 2, pp. 534-537, 1993.
192. J.-C. Liu, P. Chan, Y.-J. Chen, B. Tomlinson, S.-F. Hong, and J.-T. Cheng, "The antihypertensive effect of the berberine derivative 6-protoberberine in spontaneously hypertensive rats," Pharmacology, vol. 59, no. 6, pp. 283-289, 1999.
193. M.-H. Li, Y.-J. Zhang, Y.-H. Yu et al., "Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy," European Journal of Pharmacology, vol. 728, no. 1, pp. 67-76, 2014.
194. T. Zhang, S. Yang, and J. Du, "Protective effects of berberine on isoproterenol-induced acute myocardial ischemia in rats through regulating hmgb1-tlr4 axis," Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 849783, 8 pages, 2015.
195. L. Liu, J. Liu, Z. Huang et al., "Berberine improves endothelial function by inhibiting endoplasmic reticulum stress in the carotid arteries of spontaneously hypertensive rats," Biochemical and Biophysical Research Communications, vol. 458, no. 4, pp. 796-801, 2015.
196. Y.-J. Zhang, S.-H. Yang, M.-H. Li et al., "Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: role of autophagy," Clinical and Experimental Pharmacology and Physiology, vol. 41, no. 12, pp. 995-1002, 2014.
197. K. Chen, G. Li, F. Geng et al., "Berberine reduces ischemia/ reperfusion-induced myocardial apoptosis via activating AMPK and PI3K-Akt signaling in diabetic rats," Apoptosis, vol. 19, no. 6, pp. 946-957, 2014.
198. X.-Q. Zhou, X.-N. Zeng, H. Kong, and X.-L. Sun, "Neuroprotective effects of berberine on stroke models in vitro and in vivo," Neuroscience Letters, vol. 447, no. 1, pp. 31-36, 2008.
199. H. Dong, N. Wang, L. Zhao, and F. Lu, "Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis," Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 591654, 12 pages, 2012.
200. X.-H. Zeng, X.-J. Zeng, and Y.-Y. Li, "Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy," American Journal of Cardiology, vol. 92, no. 2, pp. 173-176, 2003.
201. W. Huang, "Ventricular tachyarrhythmias treated with berberine," Zhonghua Xin Xue Guan Bing Za Zhi, vol. 18, no. 3, pp. 155-156, 190, 1990.
202. C. Jiang and Y. Kuang, "Therapeutic efficacy of berberine in 32 arrhythmic patients," Zhong Guo Zhong Xi Yi JieHe Ji Jiu Za Zhi, vol. 5, 1998.
203. H. Dong, Y. Zhao, L. Zhao, and F. Lu, "The effects of berberine on blood lipids: a systemic reviewandmeta-analysis of randomized controlled trials," PlantaMedica, vol. 79, no. 6, pp. 437-446, 2013.
204. L. Liu, Y.-L. Yu, J.-S. Yang et al., "Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study," Naunyn- Schmiedeberg's Archives of Pharmacology, vol. 381, no. 4, pp. 371-381, 2010.
205. F. Affuso, A. Ruvolo, F. Micillo, L. Sacca, and S. Fazio, "Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study," Nutrition, Metabolism and Cardiovascular Diseases, vol. 20, no. 9, pp. 656-661, 2010.
206. J. Lan, Y. Zhao, F. Dong et al., "Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension," Journal of Ethnopharmacology, vol. 161, pp. 69-81, 2015.